BeiGene gets China NMPA’s approval for BRUKINSA for CLL/SLL and WM
BeiGene’s Bruton’s tyrosine kinase inhibitor (BTKi) BRUKINSA (zanubrutinib) has secured approvals from the China National Medical Products Administration (NMPA) for four applications. The approvals include two supplemental new